Innate Pharma (IPHA) Accounts Payables (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Accounts Payables data on file, last reported at $17.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 2.37% year-over-year to $17.5 million; the trailing twelve-month figure through Dec 2025 stood at $17.5 million (up 2.37% YoY), and the FY2025 full-year result was $17.5 million, up 2.37% from the prior year.
• Accounts Payables for Q4 2025 stood at $17.5 million, up from $13.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $32.7 million in Q4 2021 and bottomed at $13.6 million in Q2 2025.
• The 5-year median for Accounts Payables is $19.1 million (2022), against an average of $19.9 million.
• The widest annual swing landed in 2021, when Accounts Payables slumped 99.92%; it then climbed 3.82% in 2023.
• A 5-year view of Accounts Payables shows it stood at $32.7 million in 2021, then slumped by 34.73% to $21.3 million in 2022, then declined by 14.17% to $18.3 million in 2023, then retreated by 6.58% to $17.1 million in 2024, then grew by 2.37% to $17.5 million in 2025.
• The last three Accounts Payables figures came in at $17.5 million (Q4 2025), $13.6 million (Q2 2025), and $17.1 million (Q4 2024), per Business Quant data.

Peer Comparison